Milestone Phase II Clinical Study Demonstrates Niagen Patented Nicotinamide Riboside To Improve Functional Mobility For Individuals With Peripheral Artery Disease
Portfolio Pulse from Benzinga Newsdesk
A Phase II clinical study has demonstrated that Niagen, a patented nicotinamide riboside, improves functional mobility for individuals with Peripheral Artery Disease (PAD). The study showed improvements in the six-minute walking distance and treadmill walking time for participants.
June 24, 2024 | 12:38 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
ChromaDex Corporation (CDXC) is likely to see a positive impact on its stock price following the successful Phase II clinical study of its Niagen product, which showed significant improvements in mobility for individuals with Peripheral Artery Disease.
The successful Phase II clinical study of Niagen, a product by ChromaDex, demonstrated significant improvements in mobility for PAD patients. This positive outcome is likely to boost investor confidence and drive up the stock price of CDXC in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100